Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
- 27 February 2020
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (6), 1902418
- https://doi.org/10.1183/13993003.02418-2019
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Risk stratification and medical therapy of pulmonary arterial hypertensionEuropean Respiratory Journal, 2019
- Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case seriesAmerican Journal of Health-System Pharmacy, 2018
- Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 studyThe Journal of Heart and Lung Transplantation, 2018
- Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification modelEuropean Respiratory Journal, 2017
- Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertensionEuropean Respiratory Journal, 2017
- A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertensionEuropean Heart Journal, 2017
- Selexipag for the Treatment of Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2015
- Upfront triple combination therapy in pulmonary arterial hypertension: a pilot studyEuropean Respiratory Journal, 2014
- Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertensionEuropean Respiratory Journal, 2012
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionThe New England Journal of Medicine, 1996